- Study meets objective of demonstrating safety and pharmacodynamic response
- Confirmed excellent safety profile in combination with concomitant medications, with no serious adverse events
- Opens way for further development in early-onset pediatric population
Geneva, Switzerland, 7 May 2019 – 7:30am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS) and type-1 diabetes (T1D), today announced that a six-month extension of its Phase IIa study of temelimab (GNbAC1) in T1D confirmed all previouslyobserved positive observations in the trial, meeting its primary objective. GeNeuro believes these data open the door to further development in early-onset T1D pediatric patient population.
For more information,